This plain language summary of publication article (PLSP) from Future Oncology, the DESTINY-Lung01 study involves adults with metastatic non-small-cell lung cancer (NSCLC) unresponsive to surgery and prior treatments, focusing on those with HER2-mutant NSCLC. Researchers are examining if trastuzumab deruxtecan (T-DXd) can effectively treat this group. The study is ongoing at the time of this publication.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer’ and was published in The New England Journal of Medicine. 

Visit The New England Journal of Medicine using the link to read the original article.